USPTO granted US Patent No. US12590968B2 to Seagen Inc. on March 31, 2026. The patent covers methods for diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers, with 4 claims in CPC classes including C07K 16/2878 (immunoglobulins) and A61K 47/6849 (conjugates for therapeutic delivery). The original application was filed as No. 17747591 on May 18, 2022.

Pharmaceutical companies and biotechnology firms developing CD30-targeted oncology therapies should review this patent for potential freedom-to-operate implications. IP counsel should assess whether existing or planned research programs may fall within the granted claim scope. Parties interested in licensing or design-around strategies should obtain and review the full patent document to understand the precise boundaries of the 4 granted claims.